You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
愛美客(300896.SZ):2024年度淨利潤為19.58億元 擬10派38元
格隆匯 03-19 21:16

格隆匯3月19日丨愛美客(300896.SZ)公佈2024年年度報吿,2024年公司實現營業收入30.26億元,同比增長5.45%;歸屬於上市公司股東的淨利潤19.58億元,同比增長5.33%;歸屬於上市公司股東的扣除非經常性損益的淨利潤18.72億元,同比增長2.20%;基本每股收益6.50元;擬向全體股東每10股派發現金紅利38元(含税)。

報吿期內,公司溶液類與凝膠類注射產品均實現同比增長。其中,溶液類注射產品實現營業收入17.44億元,較上年同期增長4.40%;凝膠類注射產品實現營業收入12.16億元,較上年同期增長5.01%。

報吿期內,公司研發投入約3.04億元,佔營業收入的比例為10.04%;截至報吿期末,公司擁有有效授權專利163件,其中發明專利49項。

報吿期內,公司多個在研醫療器械、藥品等管線產品獲得進展。其中:用於糾正頦部後縮的醫用含聚乙烯醇凝膠微球的交聯透明質酸鈉凝膠獲得Ⅲ類醫療器械註冊證;重組透明質酸酶、司美格魯肽注射液、去氧膽酸注射液獲得國家藥品監督管理局臨牀試驗批件;米諾地爾搽劑、利多卡因丁卡因乳膏、注射用A型肉毒毒素的上市許可申請獲得受理,進入審評階段。

公司在研產品儲備豐富,已經從早期的生物材料應用技術開發到生物製藥、化學藥品的研發拓展,包括用於去除動態皺紋的A型肉毒毒素、用於軟組織提升的第二代面部埋植線、用於慢性體重管理的司美格魯肽注射液、用於溶解透明質酸可皮下注射的注射用透明質酸酶等。公司豐富的產品管線及研發儲備,為公司業務可持續發展提供保障。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account